Parkman Healthcare Partners

VYNE Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative treatments for dermatological conditions. Its flagship product, AMZEEQ, is a topical minocycline designed for the treatment of inflammatory lesions associated with moderate-to-severe acne vulgaris in patients aged nine and older. VYNE is advancing several other products, including FMX103, which is in Phase III clinical trials for moderate-to-severe papulopustular rosacea, and FCD105, a topical combination foam currently in Phase II trials for acne vulgaris. Additionally, the company is developing Serlopitant, an oral NK1 receptor antagonist aimed at alleviating pruritus linked to conditions such as prurigo nodularis. Founded in 2003 and headquartered in Bridgewater, New Jersey, VYNE Therapeutics was previously known as Menlo Therapeutics Inc. before its name change in September 2020.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation systems aimed at enhancing the treatment of arrhythmias and coronary artery disease in interventional surgical suites. The company's flagship products include the Genesis RMN and Niobe systems, which assist physicians in performing complex procedures by enabling precise, image-guided catheter navigation within the cardiovascular system. Additionally, Stereotaxis offers the Vdrive system, which provides stability and navigation for diagnostic and therapeutic devices, as well as the Odyssey solution for real-time information management in interventional labs. The company also supplies a range of disposable components and accessories, such as automated catheter advancement devices and various steerable tip catheters. Stereotaxis markets its products through direct sales, distributors, and sales agents. Established in 1990 and headquartered in St. Louis, Missouri, Stereotaxis has developed over 100 patents related to robotic cardiology technologies and maintains a strategic collaboration with Osypka AG to advance its product offerings.